Kymab’s antibody shows early promise in GvHD prophylaxis
UK group Kymab has unveiled what it says are “remarkable” early stage results for its new antibody therapy KY1005 in animal models of acute graft-versus-host-disease (GvHD).
Read More
Tag: KY1005
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
